Page 85 - GPD-4-1

Gene & Protein in Disease Sickle cell disease’s journey

disease-associated recurrent ischemic priapism: Profile and doi: 10.1002/14651858.CD002202.pub2
risk factors. J Sex Med. 2015;12:713-719.
99. Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B.
doi: 10.1111/jsm.12816 Hydroxyurea in sickle cell disease: Drug review. Indian J
Hematol Blood Transfus. 2014;30(2):91-96.
88. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan
GR. Prevalence of priapism in children and adolescents with doi: 10.1007/s12288-013-0261-4
sickle cell anemia. J Pediatr Hematol. 1999;21:518-522.
100. Tanhehco YC, Shi PA, Schwartz J. Transfusion therapy in
89. Kato GJ. Priapism in sickle-cell disease: A hematologist’s sickle cell disease. Ann Blood. 2022;7:9.
perspective. J Sex Med. 2012;9:70-78.
101. Linder GE, Chou ST. Red cell transfusion and
doi: 10.1111/j.1743-6109.2011.02287.x alloimmunization in sickle cell disease. Haematologica.
2021;106:1805-1815.
90. Allali S, De Montalembert M, Brousse V, et al. Hepatobiliary
complications in children with sickle cell disease: doi: 10.3324/haematol.2020.270546
A retrospective review of medical records from 616 patients. 102. Elenga N, Loko G, Etienne-Julan M, Al-Okka R, Adel AM,
J Clin Med. 2019;8(9):1481.
Yassin MA. Real-World data on efficacy of L-glutamine
doi: 10.3390/jcm8091481 in preventing sickle cell disease-related complications in
pediatric and adult patients. Front Med. 2022;9:931925.
91. Martins RA, Soares RS, De Vito FB, et al. Cholelithiasis
and its complications in sickle cell disease in a university doi: 10.3389/fmed.2022.931925
hospital. Rev Bras Hematol Hemoter. 2017;39:28-31.
103. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3
doi: 10.1016/j.bjhh.2016.09.009 Randomized trial of voxelotor in sickle cell disease. N Engl J
Med. 2019;381(6):509-519.
92. Essien EA, Winter-Eteng BF, Onukogu CU, Nkangha DD,
Daniel FM. Psychosocial challenges of persons with sickle doi: 10.1056/NEJMoa1903212
cell anemia: A narrative review. Medicine (Baltimore). 104. FDA News Release. FDA is Alerting Patients and Health Care
2023;102(47):e36147.
Professionals About the Voluntary Withdrawal of Oxbryta
doi: 10.1097/MD.0000000000036147 from the Market Due to Safety Concerns; 2024. Available from:
https://www.fda.gov/drugs/drug-safety-and-availability/
93. Vinjamur DS, Bauer DE, Orkin SH. Recent progress in
understanding and manipulating haemoglobin switching for fda-alerting-patients-and-health-care-professionals-about-
voluntary-withdrawal-oxbryta-market-due [Last accessed
the haemoglobinopathies. Br J Haematol. 2018;180:630-643.
on 2024 Dec 03].
doi: 10.1111/bjh.15038
105. Sagi V, Mittal A, Tran H, Gupta K. Pain in sickle cell disease:
94. Migotsky M, Beestrum M, Badawy SM. Recent Advances Current and potential translational therapies. Transl Res.
in sickle-cell disease therapies: A review of voxelotor, 2021;234:141-158.
crizanlizumab, and l-glutamine. Pharmacy (Basel). doi: 10.1016/j.trsl.2021.03.007
2022;10(5):123.
106. Dampier CD, Telen MJ, Wun T, et al. A randomized clinical
doi: 10.3390/pharmacy10050123
trial of the efficacy and safety of rivipansel for sickle cell
95. King SB. N-hydroxyurea and acyl nitroso compounds as vaso-occlusive crisis. Blood. 2023;141(2):168-179.
nitroxyl (HNO) and nitric oxide (NO) donors. Curr Top doi: 10.1182/blood.2022015797
Med Chem. 2005;5:665-673.
107. Rees CA, Brousseau DC, Cohen DM, et al. Sickle cell
doi: 10.2174/1568026054679362
disease treatment with Arginine Therapy (STArT): Study
96. Eaton WA, Bunn HF. Treating sickle cell disease by targeting protocol for a phase 3 randomized controlled trial. Trials.
HbS polymerization. Blood. 2017;129:2719-2726. 2023;24(1):538.
doi: 10.1182/blood-2017-02-765891 doi: 10.1186/s13063-023-07538-z
97. Čokić V, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea 108. Goksel E, Ugurel E, Nader E, et al. A preliminary study of
induces fetal hemoglobin by the nitric oxide-dependent phosphodiesterases and adenylyl cyclase signaling pathway
activation of soluble guanylyl cyclase. J Clin Investig. on red blood cell deformability of sickle cell patients. Front
2003;111:231-239. Physiol. 2023;14:1215835.
doi: 10.1172/JCI16672. doi: 10.3389/fphys.2023.1215835
98. Nevitt SJ, Jones AP, Howard J. Hydroxyurea 109. McArthur JG, Svenstrup N, Chen C, et al. A novel, highly potent
(hydroxycarbamide) for sickle cell disease. Cochrane and selective phosphodiesterase-9 inhibitor for the treatment of
Database Syst Rev. 2017;2017:CD002202. sickle cell disease. Haematologica. 2020;105:623-631.

Volume 4 Issue 1 (2025) 16 doi: 10.36922/gpd.4361